Inaedis


Spin-out from Princeton University (founded 2022) developing a room-temperature aerosol dehydration platform to convert liquid biologics and vaccines into dry powders for storage, transport and alternative delivery routes. The company provides R&D and laboratory-scale manufacturing services, has peer-reviewed publications validating the approach, and has received multiple government and foundation awards to advance commercialization.

Industries

biotechnology
health-care
pharmaceutical

Nr. of Employees

small (1-50)

Inaedis

Princeton, New Jersey, United States, North America


Products

Room-temperature aerosol dehydration platform

Platform process that forms ultra-fine aerosols from liquid bioformulations and dries them at room temperature to produce stable dry powders without added heat or freezing.


Services

R&D services for thermal stabilization of biologics and vaccines

Research and development services to develop and validate room-temperature powderized formulations of biologic drugs and vaccines.

Laboratory-scale and pilot-scale manufacturing services for dry powder biologics

Production services for generating laboratory-scale batches of dry powder biologic doses and preparation for pilot-scale manufacturing.

Inhaled biological drug development

Formulation and aerosolization development for high-quality inhaled biologics and inhalable powder candidates.

Expertise Areas

  • Thermostable vaccine and biologic formulation
  • Aerosol-based dehydration and liquid atomization
  • Dry powder inhalation formulation
  • Stability and potency analytical testing
  • Show More (4)

Key Technologies

  • Room-temperature aerosol dehydration
  • Submicron liquid atomization
  • Aerosol-assisted particle synthesis
  • Dry powder inhalation formulation
  • Show More (3)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.